September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
OCTA in retinal vascular diseases
Author Affiliations & Notes
  • Nadia K Waheed
    New England Eye Center/Tufts University, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Nadia Waheed, Carl Zeiss Meditech (F), Iconic Therapeutics (C), Nidek (F), Optovue (F), Thrombogenics (R)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nadia K Waheed; OCTA in retinal vascular diseases. Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : Fluorescein angiography and structural OCT has been a mainstay in the diagnosis and management of retinal vascular disease. However, with the advent of OCT Angiography (OCTA), many of the changes visible on fluorecein angiography can be visualized using OCTA. Moreover, OCTA provides depth resolved imaging of the retina, which enables us to see changes in the deep retinal vascular plexus. This session will discuss OCT angiography changes seen in retinal vascular diseases.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.